Category Archives: AZBio News
NuvOx Pharma receives FDA Orphan Drug Designation for Radiosensitizer for Glioblastoma
Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational radiosensitizer for glioblastoma multiforme.Continue reading
New Technology May Help Surgeons Save Lives
Hyalescent Ventures Makes Investment In Beacon Biomedical Inc. to Make Cancer Screening Easy, Accurate and Affordable
Beacon Biomedical, Inc., a privately held company focused on developing patient friendly cancer screening announced that it received an investment from Hyalescent Ventures.Continue reading
Accelerate Diagnostics Reports Positive Results From Pilot Study of Its Investigational ID/AST System and Blood Culture Assay Kit and Initiation of Trial to Support FDA Clearance
Accelerate Diagnostics, Inc. announced positive findings from a multicenter pilot study to evaluate external performance of its ID/AST System and Blood Culture Assay Kit. Based on the results of the study, the company also announced the initiation of its clinical trial for submission to the U.S. Food and Drug Administration.Continue reading
Sinema, Fitzpatrick Jobs Bill Cuts Red Tape for Innovators
WASHINGTON, D.C. – Dec. 1, 2015 – Today, Congresswoman Kyrsten Sinema (AZ-09) and Congressman Mike Fitzpatrick (PA-08) introduced legislation reducing burdensome regulations on small and emerging businesses. The Fostering Innovation Act provides commonsense regulatory relief for companies on the cutting edge of scientific and medical research.
Brain State Technologies Launches Kickstarter Campaign for B-2 Development
B-2 Technology helps the brain deeply relax and rebalance itself for relief from stress, refreshing sleep, and increased performance.Continue reading
NuvOx reports favorable data on Phase 1b clinical trial in Glioblastoma multiforme (GBM)
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions.
Continue reading